SUBSCRIBE: Print / Digital / eNewsletter
Researchers have described a new class of pseudogene-associated fusion transcript in prostate cancer that has potential application as a therapeutic target and biomarker for early prostate cancer detection.
Men who take statins for at least 11 months might be at lower risk for low- and high-Gleason grade prostate cancer than men who do not take the cholesterol-lowering drugs, according to a recent study.
"Of note, the number needed to treat analysis revealed that 18 patients treated with ADT resulted in one patient being diagnosed with Alzheimer’s and 10 patients treated with ADT resulted in one patient with a dementia diagnosis," writes Badar M. Mian, MD.
Three novel androgen receptor inhibitors provide an embarrassment of riches when it comes to treatment options for nmCRPC patients, but there are still questions to be answered—including the extent of these drugs’ clinical benefit.
Findings from 18-fluciclovine (Axumin) positron emission tomography/computed tomography imaging had a major impact on management decisions for men with biochemical recurrence of prostate cancer.
Published findings from PROCEED, a large registry collecting data from men treated with sipuleucel-T (Provenge) for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer, provide valuable insight on real-world outcomes associated with this immunotherapy agent in the modern era of prostate cancer management.
The FDA has approved apalutamide (Erleada) for the treatment of patients with metastatic castration-sensitive prostate cancer, a new indication for the next-generation androgen receptor inhibitor.
A preliminary study of the use of salvage lymph node dissection in patients with nonmetastatic, castration-resistant prostate cancer indicates the potential to delay disease recurrence as well as the use of systemic therapies through this approach.
A new study suggests that prostate-specific membrane antigen positron emission tomography/computed tomography may be a highly beneficial tool for initial staging of high-risk and high-intermediate-risk prostate cancer.
Researchers say the use of apalutamide (Erleada) in patients with high-risk, nonmetastatic castration-resistant prostate cancer improves metastasis-free survival in patients who have previously undergone radical prostatectomy or external radiotherapy—regardless of the type of treatment they received.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
